25 October 2021 - Under the guise of Medicare ‘negotiations,’ the US House of Representatives is considering a measure that would mandate the government to set prices on some of the most widely used drugs.

Critics argue that the United States is the only developed country where the federal government doesn’t negotiate prescription drug prices and that a 40% cut to the pharmaceutical industry’s size will have limited or no impact on future cures or pandemic preparedness.

If it all sounds too good to be true, that’s because it is.

Read Boston Globe article